Lung Cancer

21 protocols meet the specified criteria

OCR17388

A Phase 1 Study of Pembrolizumab (MK-3475) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors

OCR31222

A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors

OCR31722

Clinically-Efficient Strategies to Address Tobacco Smoke Exposure in Pediatric Practice

OCR37042

Phase 2 Trial Evaluating the Safety and Tolerability of Intratumoral Injections of NanoPacĀ® with Standard of Care Therapy in Subjects with Lung Cancer

OCR37342

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations

OCR38804

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial

OCR38884

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations

OCR39693

A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

OCR40290

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumor Malignancies

OCR40627

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

OCR40664

Precision Cancer Survivorship Cohort

OCR40891

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

OCR40933

Reducing Tobacco-Associated Lung Cancer Risk: A Randomized Clinical Trial of AB-Free Kava

OCR41086

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

OCR41183

Social Media Anti-Vaping Messages to Reduce ENDS Use Among Sexual and Gender Minority Teens

OCR41407

A Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Safety and Efficacy of Adoptive Cell Therapies in Participants with Solid Tumors and Hematologic Malignancies

OCR41744

Increasing patient portal adoption among Black cancer patients: Designing messaging and identifying proper communication channels

OCR41889

Cancer Knowledge, Quality of Life, Health Behaviors, and Views About Health Care and Medical Research among Adult Cancer Survivors and Adults At-Risk for Cancer: A Study by the UF Health Cancer Center s Community-Partnered Cancer Disparities Research Collaborative

OCR41944

Population Health Assessment in the UFHCC Catchment Area Random Digit Dialing Survey: Cancer Screening Knowledge and Health Habits in the UFHCC Catchment Area

OCR42090

A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response

OCR42568

Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas